These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The role of orlistat in weight management. Marks S Aust Fam Physician; 2001 Apr; 30(4):335-8. PubMed ID: 11355219 [TBL] [Abstract][Full Text] [Related]
23. Orlistat for the treatment of obesity: cost utility model. Foxcroft DR Obes Rev; 2005 Nov; 6(4):323-8. PubMed ID: 16246217 [TBL] [Abstract][Full Text] [Related]
24. Orlistat--a novel weight loss therapy. Lucas KH; Kaplan-Machlis B Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530 [TBL] [Abstract][Full Text] [Related]
25. Orlistat (Xenical) in the management of obesity. Cheah JS Ann Acad Med Singap; 2000 Jul; 29(4):419-20. PubMed ID: 11056767 [No Abstract] [Full Text] [Related]
26. Orlistat in the treatment of obesity. Ballinger A Expert Opin Pharmacother; 2000 May; 1(4):841-7. PubMed ID: 11249520 [TBL] [Abstract][Full Text] [Related]
27. Orlistat, a new lipase inhibitor for the management of obesity. Heck AM; Yanovski JA; Calis KA Pharmacotherapy; 2000 Mar; 20(3):270-9. PubMed ID: 10730683 [TBL] [Abstract][Full Text] [Related]
29. Orlistat: its current status as an anti-obesity drug. Ballinger A; Peikin SR Eur J Pharmacol; 2002 Apr; 440(2-3):109-17. PubMed ID: 12007529 [TBL] [Abstract][Full Text] [Related]
30. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach. Hertzman P Pharmacoeconomics; 2005; 23(10):1007-20. PubMed ID: 16235974 [TBL] [Abstract][Full Text] [Related]
31. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Foxcroft DR; Milne R Obes Rev; 2000 Oct; 1(2):121-6. PubMed ID: 12119985 [TBL] [Abstract][Full Text] [Related]
32. Benefit-risk assessment of orlistat in the treatment of obesity. Sumithran P; Proietto J Drug Saf; 2014 Aug; 37(8):597-608. PubMed ID: 25064699 [TBL] [Abstract][Full Text] [Related]
33. [Use of orlistat (xenical) in the treatment of women with obesity and disorders of menstrual cycle]. Totoian ES; Frolova NG; Manasian AS; Akopian MA; Magevosian AA; Arutiunian ZhS Georgian Med News; 2006 Oct; (139):20-2. PubMed ID: 17077458 [TBL] [Abstract][Full Text] [Related]
34. Orlistat: a review of its use in the management of obesity. Henness S; Perry CM Drugs; 2006; 66(12):1625-56. PubMed ID: 16956313 [TBL] [Abstract][Full Text] [Related]
35. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. Pace DG; Blotner S; Guerciolini R J Nutr; 2001 Jun; 131(6):1694-9. PubMed ID: 11385055 [TBL] [Abstract][Full Text] [Related]
36. Medications for obesity: mechanisms and applications. Bray GA Clin Chest Med; 2009 Sep; 30(3):525-38, ix. PubMed ID: 19700050 [TBL] [Abstract][Full Text] [Related]
37. Orlistat for the long-term management of obesity. Seidner DL Curr Gastroenterol Rep; 1999 Aug; 1(4):316-8. PubMed ID: 10980966 [No Abstract] [Full Text] [Related]
38. Orlistat (Xenical). MacConnachie AM Intensive Crit Care Nurs; 1999 Oct; 15(5):298-9. PubMed ID: 10808826 [TBL] [Abstract][Full Text] [Related]
39. [What is the evidence with regard to the effectiveness of orlistat?]. Nordmann A Schweiz Med Wochenschr; 2000 Apr; 130(17):629-34. PubMed ID: 10829301 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. van Baal PH; van den Berg M; Hoogenveen RT; Vijgen SM; Engelfriet PM Value Health; 2008 Dec; 11(7):1033-40. PubMed ID: 18494748 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]